Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Acne medication may be the solution when hair starts falling out

A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.

Nextcell Pharma rekryterar ny CFO inför internationell expansion

Biotechbolaget Nextcell Pharma har utsett Eric Gustafsson till ny finanschef (CFO). Han tillträder den 15 december.

CTC Clinical Trial Consultants AB

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...

GU Ventures AB

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

Merck Life Science A/S

Clinigen Clinical Supplies Management GmbH

Tummen upp för fördröjande behandling av typ 1-diabetes

En ny behandling för att bromsa insjuknandet i typ 1-diabetes rekommenderas för godkännande i EU.

Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.

Precision medicine centre: “Extensive activity on several fronts”

Two years ago, the Karolinska Institutet and the Karolinska University Hospital announced that they would jointly launch the Precision Medicine Centre. Medtech ...

EU har nått läkemedelsuppgörelse – ”Inte tillräckligt”

Efter fleråriga förhandlingar har EU nått en preliminär uppgörelse om ett omfattande läkemedelspaket. Uppgörelsen innebär bland annat att kommissionens omstridd...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Pharma Outsourcing – Find the Right Partner (2026)

Eli Lilly värvar toppforskaren Kaj Blennow – ska leda Alzheimerprojekt

Eli Lilly rekryterar Kaj Blennow, en av Sveriges och världens främsta forskare inom Alzheimers sjukdom, till en post som Vice President of Neuroscience Biomarker Development.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work...

Will the FDA’s new transparency policy extend to medical devices? (Part 1)

In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...